Business
Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T (PYX-106) Presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting
- Data highlight PYX-106’s differentiated activity profile and antitumor activity in an in vivo mouse model - - Preclinical data support IND filing in 2H 2022
About this update from Pyxis Oncology, Inc.
[{"type":"text","content":"- Data highlight PYX-106’s differentiated activity profile and antitumor activity in an in vivo mouse model - - Preclinical data support IND filing in 2H 2022 - CAMBRIDGE, Mass. and NEWARK, Del. and NANJING, China, April 08, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS) today announced preclinical data supporting the potential of anti-Siglec-15 BSI-060T (now PYX-106) presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting, taking place in New Orleans, Louisiana, April 8-13, 2022. “While immunotherapies hold immense potential to improve the lives of patients with cancer, current therapeutics have demonstrated success in only a narrow range of tumor types,” said Ronald Herbst, Ph.D., Chief Scientific Officer of Pyxis Oncology. “We believe that the key to improving response rates is targeting novel pathways involved in immune suppression. The data from this presentation strongly support that PYX-106 may be an effective weapon in the otherwise limited arsenal of checkpoint inhibitors. We look forward to working with Biosion and advancing PYX-106 to the clinic and to patients in need.” Hugh M. Davis, Ph.D., Chief Operating Officer, Biosion, Inc. and President, Biosion USA, Inc. added, “These data provide clear support for the potential of PYX-106 and highlight its differentiated activity profile. We believe that its high binding affinity together with its ability to overcome Siglec-15-mediated T cell inhibition are critical for inducing a robust anti-tumor immune response. Additionally, its long half-life, as demonstrated in our non-human primate studies, suggests that PYX-106 could provide extended coverage of the target, which will be important for driving responses as a single agent and in combination with other modalities, including other immune-therapies.” Presentation Details: Title: BSI-060T, a high affinity, fully human anti-Siglec-15 antibody as an alternative immune checkpoint blockerAbstract #: 5522 Key findings from the presentation include: PYX-106 binds to Siglec-15 with high affinity and blocks the interaction between Siglec-15 and its putative receptor in vitroPYX-106 shows cross-reactivity to monkey and mouse Siglec-15 in vitroIn ex vivo T cell response assays, PYX-106 relieves Siglec-15-mediated inhibition of CD8+ and CD4+ T cell proliferation and interfer...